Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA) today announced that the US Food and Drug Administration (FDA) has approved its generic version of Tribenzor (olmesartan medoxomil, amlodipine and hydrochlorothiazide) tablets and is in the final stages of its marketing launch. Teva also recently received FDA approval and launched generic Azor (amlodipine and olmesartan medoxomil) tablets. These products enhance Teva’s antihypertensive portfolio for the treatment of high blood pressure.
Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. Many patients will require more than one drug to achieve their blood pressure goals.
Teva says it is committed to strengthening its generics business through continued investment in complex, high-quality products. With nearly 600 generic medicines available, Teva has the largest portfolio of FDA-approved generic products on the market. Teva also has over 300 product registrations pending FDA approval and holds the leading position in first-to-file opportunities, with over 100 pending first-to-files in the U.S. Currently, one in six generic prescriptions dispensed in the U.S. is filled with a Teva generic product.
Tribenzor had annual sales of $240 million in the US and Azor had annual sales of $354.1 million in the US, according to IMS data as of August 2016.
Published by Globes [online], Israel business news - www.globes-online.com - on November 7, 2016
© Copyright of Globes Publisher Itonut (1983) Ltd. 2016